<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">VÉGVÁRY, ZOLTÁN</style></author><author><style face="normal" font="default" size="100%">DARÁZS, BARBARA</style></author><author><style face="normal" font="default" size="100%">PACZONA, VIKTOR</style></author><author><style face="normal" font="default" size="100%">DOBI, ÁGNES</style></author><author><style face="normal" font="default" size="100%">REISZ, ZITA</style></author><author><style face="normal" font="default" size="100%">VARGA, ZOLTÁN</style></author><author><style face="normal" font="default" size="100%">FODOR, EMESE</style></author><author><style face="normal" font="default" size="100%">CSERHÁTI, ADRIENN</style></author><author><style face="normal" font="default" size="100%">OLÁH, JUDIT</style></author><author><style face="normal" font="default" size="100%">KIS, DÁVID</style></author><author><style face="normal" font="default" size="100%">BARZÓ, PÁL</style></author><author><style face="normal" font="default" size="100%">HIDEGHÉTY, KATALIN</style></author></authors><secondary-authors></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Adaptive Radiotherapy for Glioblastoma Multiforme – The Impact on Disease Outcome</style></title><secondary-title><style face="normal" font="default" size="100%">Anticancer Research</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2020</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2020-08-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">4237-4244</style></pages><doi><style  face="normal" font="default" size="100%">10.21873/anticanres.14425</style></doi><volume><style face="normal" font="default" size="100%">40</style></volume><issue><style face="normal" font="default" size="100%">8</style></issue><abstract><style  face="normal" font="default" size="100%">Background/Aim: To study the changes of glioblastoma multiforme during chemoradiotherapy (CRT) and to evaluate the impact of changes on dosimetry and clinical outcomes. Patients and Methods: Forty-three patients underwent volumetric imaging-based replanning. Prognostic factors and gross tumor volume changes in relation to overall survival and the effect of adaptive replanning were statistically analyzed. Results: Patients with total tumor removal, with shorter time to CRT (&lt;27 days), with methylated O-6 methylguanine DNA methyltransferase and good performance status (&gt;60%) had better survival. Tumor shrinkage in 24 patients resulted in improved survival compared to 19 in whom tumor was unchanged or progressed (25.3 vs. 11.1 months, p=0.04). Adapted planning target volume allowed a reduction in irradiated volume, while increasing survival (12.06 vs. 28.98 months, p=0.026). Conclusion: Tumor response during CRT has significant impact on the outcome. Adaptation of the planning target volume to the tumor changes proved to be beneficial and warrants further investigation.</style></abstract></record></records></xml>